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Abstract: Toluene diisocyanate (TDI) is a potent low molecular weight chemical sensitizer and
a leading cause of chemical-induced occupational asthma. The regulatory potential of microRNAs
(miRNAs) has been recognized in a variety of disease states, including allergic disease; however,
the roles of miRNAs in chemical sensitization are largely unknown. In a previous work, increased
expression of multiple miRNAs during TDI sensitization was observed and several putative mRNA
targets identified for these miRNAs were directly related to regulatory T-cell (Treg) differentiation
and function including Foxp3 and Runx3. In this work, we show that miR-210 expression is increased
in the mouse draining lymph node (dLN) and Treg subsets following dermal TDI sensitization.
Alterations in dLN mRNA and protein expression of Treg related genes/putative miR-210 targets
(foxp3, runx3, ctla4, and cd25) were observed at multiple time points following TDI exposure and in
ex vivo systems. A Treg suppression assay, including a miR-210 mimic, was utilized to investigate
the suppressive ability of Tregs. Cells derived from TDI sensitized mice treated with miR-210 mimic
had less expression of miR-210 compared to the acetone control suggesting other factors, such as
additional miRNAs, might be involved in the regulation of the functional capabilities of these cells.
These novel findings indicate that miR-210 may have an inhibitory role in Treg function during TDI
sensitization. Because the functional roles of miRNAs have not been previously elucidated in a model
of chemical sensitization, these data contribute to the understanding of the potential immunologic
mechanisms of chemical induced allergic disease.
Keywords: microRNA; regulatory T cell; immunotoxicology; toluene diisocyanate; isocyanate; miR-210
1. Introduction
Occupational allergic disease is a significant health burden. A variety of diseases can be caused by
workplace chemical exposures, including asthma, conjunctivitis, dermatitis, rhinitis, and urticaria [1].
Diisocyanates are a group of highly reactive chemicals characterized by the presence of double
isocyanate functional groups; many of these chemicals are potent sensitizers and major causative
agents of occupational allergic disease [2–4]. Toluene diisocyanate (TDI) is frequently utilized in
the automobile industry and in the manufacture of polyurethane foams, paints, and coatings [5–8].
TDI is widely used throughout the U.S. and around the globe; the U.S. Environmental Protection
Agency reports that U.S. production and importation of 2–4 and 2–6 TDI isomers rose above one
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billion pounds in 2006 [6]. While TDI has generally been classified as a T-helper type 2 (Th2) sensitizer,
the immune response following exposure is more accurately characterized as a mixed Th1/Th2
response in both rodents and humans [1,2,9]. The principal routes of human exposure to TDI are
inhalation and dermal contact [6] and sensitization leading to allergic disease has been documented
for both routes [7,10]. Once the induction threshold has been reached, skin sensitization is thought to
be sufficient for subsequent allergic disease of the respiratory tract [7], illustrating the systemic nature
of TDI sensitization. Although TDI-induced allergic disease is an extremely relevant occupational
health concern the pathogenic mechanisms of diisocyanate-induced allergic disease are not fully
understood [5]. The identification of novel mediators of allergic disease may be necessary to obtain
a full and complete understanding of the disease. Because of the occupational significance of and lack
of validated identification strategies for chemical respiratory sensitizers like TDI [4,11], it is necessary
to investigate and identify functional pathways and mechanisms that are involved in TDI sensitization.
Specific understanding of disease mechanism may have direct implications in risk assessment, hazard
communication and guidance used in the selection of safe products, work place interventions and
training programs to warn workers about potential risks, the identification of safer alternatives, and the
selection of proper personal protective equipment (PPE).
An emerging class of epigenetic regulatory elements that have been the subject of recent scientific
focus are microRNAs (miRNAs). These molecules are single stranded, noncoding RNA molecules
that are approximately 19–23 nucleotides long [12]. miRNAs exhibit functional significance though
posttranscriptional gene regulation due to their ability to bind to the target mRNA and destabilize
and inhibit protein translation when in complex with Argonaute proteins and the RNA-induced
silencing complex (RISC). The seed sequence of a mature miRNA interacts with the 3′ untranslated
region of target mRNA and leads to the translational repression or degradation of the target mRNA,
influencing gene expression. Recently, it has been shown that miRNAs play a major role in a variety of
immune responses [13–16]. These regulatory factors have not been functionally investigated in the
context of chemical sensitization, with the exception of recent work by our group that profiled the
general expression kinetics of miRNAs involved in TDI sensitization [1] and research profiling miRNA
expression in both human and murine diphenylcyclopropenone-induced dermatitis [17].
The identification of increased expression of several miRNAs in the draining lymph nodes (dLN)
of mice during epicutaneous TDI sensitization prompted further investigation into the potential
functional roles of these molecules in the allergic response. Target analysis for upregulated miRNAs
(miR-210, -31, and -155) revealed several putative and confirmed regulatory T cell (Treg)-related targets
including foxp3 and runx3 in murine and human genomes [1]. These transcription factors and the
signaling molecules CD25 and CTLA4 are integral to Treg differentiation and function. The expression
of these molecules allows Treg to differentiate in response to allergens and exert immunoregulatory
functions, dampening inappropriate inflammatory and adaptive immune responses. In addition,
miR-31 and -155 have been implicated as regulators of Treg in a variety of contexts [18,19]. A role
for Tregs has been suggested in models of chemical-induced contact hypersensitivity [20,21] and,
in a recent manuscript, Long et al. demonstrated the increased expression and functional capability of
Tregs during TDI sensitization [21]. While the collection of data regarding roles for Tregs and miRNAs
in chemical allergy is growing, it is still limited. Recently published data suggests an important role
for Tregs in dermal TDI sensitization, yet the interaction between these cells and selected miRNAs
has not been investigated. While miR-210 is well characterized in the hypoxia response, its specific
role in allergic disease has not yet been defined. In the present study, we utilized a murine model of
epicutaneous TDI sensitization in order to elucidate the expression kinetics and role of miR-210 and its
putative mRNA targets in a murine model of epicutaneous TDI sensitization, specifically in relation to
the Treg subset.
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2. Materials and Methods
2.1. Mice
Female BALB/c mice (6–8 weeks of age) were obtained from Taconic (Germantown, NY,
USA), acclimated for 5 days, and then randomly assigned to treatment group; homogenous weight
distribution was ensured across treatment groups. Mice were housed in ventilated plastic shoebox
cages with hardwood chip bedding at a maximum of five animals per cage. A NIH-31 modified 6%
irradiated rodent diet (Harlan Teklad, Frederick, MD, USA) and tap water were administered ad
libitum. Housing facilities were maintained at 68–72◦F and 36%–57% relative humidity, and a 12 h
light–dark cycle was maintained. All animal experiments were performed in the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited National Institute
for Occupational Safety and Health (NIOSH) animal facility in accordance with an Institutional
Animal Care and Use Committee-approved protocol (protocol number 15-SA-M-004, date of approval
1 August 2015).
2.2. TDI Sensitization Model
Toluene 2,4-diisocyanate (TDI, CAS# 584-84-9) was obtained from Sigma-Aldrich (Milwaukee,
WI, USA). Animals were exposed to a single dose of 0%, 0.5%, and 4% TDI (v/v) on the dorsal surface
of each ear (25 µL per ear). The chosen TDI concentrations (0.5% and 4% v/v) and dosing regimen
was previously shown to induce sensitization [1,21] and 4% TDI (1000 µg TDI/cm2) was previously
reported as the minimum single dose concentration of TDI that could induce maximum sensitization
in the absence of systemic toxicity [1]. Acetone was selected as the vehicle control and has been
historically utilized in our laboratory to evaluate chemical sensitization [21–23]. It is important to
note that due to hydrolysis, slight variations in the concentration of TDI dosing solutions may have
occurred between preparation and application. However, animals were exposed within 30 min of TDI
preparation and no visualization of hydrolysis was observed subsequent to exposures.
2.3. Euthanasia, Tissue Collection, and Processing
Animals were weighed, euthanized via CO2 asphyxiation at time points ranging from 1 to 11 days
post chemical exposure, and examined for gross pathology. Left and right auricular draining lymph
nodes (dLNs; drain the site of chemical application) were collected in 4 mL sterile phosphate-buffered
saline (PBS, pH 7.4) and manually dissociated using the frosted ends of two microscope slides. Cells
were counted using a Cellometer (Nexcelom Bioscience, Lawrence, MA, USA) and size exclusion
parameters (3.5 to 36 µm) with a combined acridine orange/propidium iodide solution to identify
viable cells. For isolation of specific cellular subsets Stemcell magnetic isolation kits (Vancouver, BC,
Canada) were utilized, including the Treg isolation kit (CD4 negative and CD25 positive selection).
2.4. Ex Vivo miRNA Transfection Assays
Following dLN processing and counting, miR-31, -155, and -210 mimics (25 pmol in Lipofectamine
transfection reagent, ThermoFisher, Waltham, MA, USA) were reverse transfected in flat-bottom
24-well plates for 24 h. Then, 1.5 × 106 naïve or acetone-treated dLN cells/mL (in RPMI-1640 media)
were added to plates followed by general T cell stimulation (2 µg/mL α-CD3, 1 µg/mL α-CD28
and incubated in fresh media at 37 ◦C and 5% CO2. Following a 72 h incubation, cells were washed
with RPMI-1640 and RNA was isolated as described in the following section. RNA was assayed for
intracellular miRNA expression to conform the intracellular uptake of miRNA mimics as well as
Treg-related gene expression via RT-PCR.
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2.5. RNA Isolation, Reverse Transcription, and RT-PCR
Total RNA was isolated from the dLN using the miRNeasy kit (Qiagen, Hilden, Germany)
according to the manufacturer’s directions. A QiaCube (Qiagen) automated RNA isolation machine
was utilized in conjunction with the specified RNA isolation kit. The concentration and purity
of the RNA was determined using a ND-1000 spectrophotometer (Thermo Scientific Nanodrop,
Wilmington, DE, USA). For gene and primary miRNA expression analysis, first strand cDNA synthesis
was performed using a High-Capacity cDNA Synthesis Kit (Applied Biosystems, Carlsbad, CA,
USA) according to the manufacturer’s recommendations. For mature miRNA, reverse transcription
TaqMan MicroRNA Assays (looped-primer RT-PCR; Applied Biosystems) were utilized according to
manufacturer’s recommendations (both multiplex and singleplex protocols were utilized).
For analysis of mRNA and primary miRNA expression, TaqMan Universal Fast master mix
(Life Technologies, Carlsbad, CA, USA), cDNA, and mouse-specific mRNA primers (TaqMan Custom
PCR Arrays, Carlsbad, CA, USA) were combined and PCR was performed according to the
manufacturer’s protocol (TaqMan Gene Expression Analysis). For analysis of miRNA expression,
TaqMan Universal 2×master mix, No AmpErase UNG (Life Technologies), cDNA, and mouse-specific
miRNA primers (TaqMan Custom PCR Arrays) were combined and PCR was performed according
to manufacturer protocol (TaqMan miRNA Assays both Single- and Multi-Plex). Primers used
include: β-actin, cd25 (il2rα), ctla4, foxp3, mature miR-210, -31, -155, primary miR-210, runx3, and sno234.
MicroAmp Fast Optical 96-well reaction plates were analyzed on an Applied Biosystems 7500 Fast
Real Time PCR system using cycling conditions as specified by the manufacturer. β-actin (mRNA and
primary miRNA) and snoRNA234 (miRNA) were used as the endogenous reference control gene as
expression was determined to be stable following chemical exposure (data not shown). RT-PCR data
were collected and represented as relative fold change over vehicle control, calculated by the following
formula: 2−∆∆Ct = ∆CtSample − ∆CtControl. ∆Ct = CtTarget − Ctβ-ACTIN, where Ct = cycle threshold as
defined by manufacturer.
2.6. Flow Cytometric Analysis and Treg Phenotyping
Single cell suspensions were prepared from tissues and a minimum of 150,000 dLN cells were
aliquoted into 96-well U-bottom plates and washed in fluorescence-activated cell sorting (FACS)
staining buffer (PBS + 1% bovine serum albumin + 0.1% sodium azide). Cells were resuspended
in staining buffer containing anti-mouse CD16/32 antibody (clone 2.4G2; BD Biosciences, San Jose,
CA, USA) for blocking of Fc receptors to minimize nonspecific binding. Cells were resuspended in
staining buffer containing a cocktail of fluorochrome-conjugated antibodies specific for cell surface
antigens including: CD3 (500A2, V500, BD Biosciences, Franklin Lanes, NJ, USA), CD4 (RM4-5, AF700,
BD), CD8a (53-6.7, AF488, BioLegend, San Diego, CA, USA), CD25 (PC61, APC Cy7, BioLegend),
CD45 (30-F11, PE, BD). Following surface staining, cells were washed in staining buffer and fixed
using the Foxp3 fixation buffer set (eBioscience, San Diego, CA, USA). After overnight incubation
in staining buffer, cells were permeablilized using the Foxp3 fixation buffer set (eBioscience) and
re-suspended in permeabilization buffer containing a cocktail of fluorochrome-conjugated antibodies
specific for intracellular antigens including: RUNX3 (R3-5G4, PE, BD), Foxp3 (FLK-16s, eF450 and
APC, eBioscience). Following staining, cells were re-suspended in staining buffer and analyzed on
an LSR II flow cytometer using FacsDiva software (BD Biosciences). Data analysis was performed with
FlowJo 10.0 software (TreeStar Inc., Ashland, OR, USA). A minimum of 10,000 events were captured
for each sample. Leukocytes were first identified by their expression of CD45. The Treg subset was
further identified as CD3+CD4+CD8−CD25+Foxp3+. Numerical population values were calculated by
applying subset frequencies to the initial cell count obtained following lymph node homogenization.
Compensation controls were performed using single stained cellular suspensions and OneComp beads
(eBioscience, San Diego, CA, USA) and fluorescence minus one (FMO) staining controls were included
to help set gating boundaries.
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2.7. Treg Suppression Assay
The suppressive ability of Tregs was analyzed using an ex vivo Treg suppression assay as described
by Long et al. [21] with modifications. This assay evaluates the ability of naïve, conventional
dLN-derived T cells (Tcons) to proliferate in the presence of varying numbers of Tregs isolated from
acetone- or TDI-exposed mice. Mice were exposed to acetone (n = 7–11) or TDI (4%) (n = 4–5) as
previously described and following sacrifice at 7 days (peak of the expansion) post TDI exposure the
dLN and spleens were removed. Tregs (CD4+CD25+) and Tcons (CD4+CD25−) were isolated from the
lymph nodes and CD4− accessory cells were isolated from naïve spleens using CD4 negative and
CD25 positive selection-based magnetic separation kits (Stemcell, Vancouver, BC, USA). Average Treg
purity is as follows for 7 days. Acetone: 96.5% ± 0.8% of CD3+CD4+ cells. 4% TDI: 97.35% ± 0.25%
of CD3+CD4+ cells. Following isolation from naïve mouse dLNs, Tcons were labeled with 2 µM
carboxyfluorescein succinimidyl ester (CFSE). miR-210 mirVana mimic (2 pmol; ThermoFisher) in
Lipofectamine RNAiMAX (ThermoFisher) or Lipofectamine only control (LO) were added to a 96-well
U-bottom plate in order to reverse transfect cells. Tcons and Tregs were cultured in a 96-well U-bottom
plate with anti-CD3 (0.2 µg/mL; BD Biosciences) and accessory cells (naïve CD4− splenocytes treated
with mitomycin C) at a variety of Tcon:Treg ratios (1:1, 2:1, 4:1, and 8:1). Additional controls included
stimulated Tcons only to assess baseline proliferation, Tregs only, accessory cells only, and Tcons only
with no stimulation nor accessory cells. Cells from each treatment group were pooled and added
to triplicate wells of the culture plate. Seventy-two hours following plating, cells were stained with
anti-CD4 and Live/Dead Violet (Life Technologies). Tcons were defined as CD4+CFSE+ cells and
suppression was measured based on changes in the frequency of dividing CFSE+ cells based on the
dilution of CFSE. Tregs were analyzed for purity based on their expression of CD3, CD4, and Foxp3 as
determined by flow cytometric analysis as previously described.
2.8. Statistical Analysis
Statistical analyses were generated using GraphPad Prism version 5.0 (San Diego, CA, USA).
Data were analyzed by a Student t-test comparing groups as indicated in the figure legends. Figure 4C
was analyzed by analysis of variance using PROC MIXED. In some cases, data were transformed
using the natural log to meet the assumptions of the analysis. Significant interactions were explored
utilizing the “slice” option in PROC MIXED and pairwise differences were assessed using a Fisher’s
Least Significant Difference Test. All differences were considered significant at p < 0.05; representative
significance symbols varied by figure, as indicated in the legend.
3. Results
3.1. Examination of miR-210 Expression during TDI Sensitization
The kinetics of mature miR-210 expression were investigated via RT-PCR in the dLN following
0.5% and 4% TDI exposure. As previously reported [1], dLN miR-210 increased at various time
points during 0.5% and 4% TDI sensitization, including four (4%), seven, and nine (0.5% and 4%)
days post single exposure, with expression appearing to peak at four days post 4% TDI exposure
(Figure 1A). Primary miRNA (pri-miRNA) transcripts represent the early precursor stage of mature
miRNA structure prior to modification and cleavage by Drosha and Dicer. Pri-miR-210 levels were
analyzed in the dLN at four days post TDI exposure, which represents the relative peak of dLN
miR-210 expression. Although expression of pri-miR-210 was detected in the dLN, no significant
alterations were observed. Alternatively, pri-miR-210 expression significantly decreased in the CD4+
subset during 4% TDI sensitization (Figure 1B).
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Figure 1. Mature and primary miR-210 expression increases in the draining lymph node (dLN) and
CD4+ subsets following toluene diisocyanate (TDI) sensitization: RT-PCR analysis of mature miR-210
expression in the dLN at various time points post TDI exposure (A); and primary miR-210 expression
in the whole dLN and dLN CD4+ subset four days post TDI exposure (B). Cellular purity was assessed
via flow cytometric staining for CD4+ Cells (% CD4+ of all cells; Acetone: 89.6% ± 2.2%, 0.5% TDI:
91.5% ± 0.3%, and 4% TDI: 90.4% ± 0.3%). Ba s epresent mean relative fold change (± standard
error, SE) of 3–5 mice per group. Statistical significanc is represented by ˆ (0.5% TDI) and * (4% TDI)
(p < 0.05) compared to vehicle control.
3.2. Ex Vivo miR-210 Mimic Transfection Reveals Potential Inhibitory Effect of miR-210 on Treg-Related Genes
Due to the putative link between miR-210 and Treg-related targets in both human and mouse-based
studies and target algorithms [1], an ex vivo transfection and stimulation assay was set up to directly
examine miR-210 and Treg-related gene expression. Analysis of Treg-related gene expression induced
by the addition of excess levels of miR-210 was examined. Although not statistically significant,
Figure 2A reveals increased miR-210 expression in cells treated with miR-210 mimic (101 fold) as
compared to lipofectamine only ( O) control (1.2 fold). Analysis of Treg-related genes revealed
decreased trends of expression of Treg-related genes following miR-210 mimic transfection compared
to the LO control, including foxp3 (~−2.0 fold compared to 0.6 fold) and cd25 ((~−3.2 fold compared to
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Figure 2. Ex vivo miR-210 mimic augmentation reveals potential inhib tory effect f miR-210 on
regulatory T cell (Treg)-related genes in dLN cells. (A) Intracellular miR-210 was quantified via RT-PCR
in ex vivo stimulated samples 72 h following transfection with lipofectamine only control (LO) or
miR-210 mimic. (B) foxp3 and cd25 (il2rα) were investigated as potential miRNA targets via RT-PCR.
Bars represent mean relative fold change (± SE) of 3 replicates per group.
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3.3. In Vivo dLN Target Expression Reveals Decreased Expression of Several Key Treg-Related Genes
The expression of potential miR-210 targets and key Treg genes potentially affected by miR-210
was investigated in the whole dLN at various time points following 4% TDI exposure. Similar to
the findings of the ex vivo study and previously reported findings, dLN target/key player mRNA
expression was significantly decreased at four (runx3), seven (foxp3), and nine (foxp3) days post 4% TDI
exposure (Figure 3A,B). Foxp3 expression was decreased by approximately threefold in comparison to
the acetone control at seven and nine days post TDI exposure (Figure 3A). Early statistically significant
increases in foxp3 (one day) and runx3 (two day) were also observed but only for a single time point and
not determined to be of biological significance. dLN ctla4 and cd25 expression significantly increased
with peak expression at four and two days post 4% TDI exposure, respectively. However, these
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Figure  3.  In  vivo dLN mRNA  expression of potential miR‐210  targets  reveals  altered  expression 
during TDI sensitization. RT‐PCR analysis of: foxp3 (A); runx3 (B); ctla4 (C); and cd25 (D) expression 
in the whole dLN at various time points post 0% and 4% TDI exposure. Bars represent mean relative 
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Figure 3. In vivo dLN mRNA expression of potential miR-210 targets reveals altered expression during
TDI sensitization. RT-PCR analysis of: foxp3 (A); runx3 (B); ctla4 (C); and cd25 (D) expression in the
whole dLN at various time points post 0% and 4% TDI exposur . Bars represent mean relative fold
change (± SE) of five mice per g up. Statistical significance is represented by * (p < 0.05) compared to
the vehicle control.
3.4. Treg-Specific miRNA and Gene Expression
Due to the suspected influence of miR-210 on Tr gs, the levels of this miRNA were examined in
Tregs (CD4+CD25+) from the LN of mice tre ed with 0%, 0.5%, d 4% TDI at two and seven days
post exposure. These time points were selected to reflect early and peak miR-210 and Treg responses
in the dLN (Figure 1A and [1]). While no statistically significant changes were observed following
two days of exposure, miR-210 levels were significantly increased in Tregs during 0.5% and 4% TDI
sensitization in a dose responsive fashion at seven days post exposure (Figure 4A). Expression of
Treg-related genes was also examined in isolated Tregs following TDI exposure. Significant decreases
in foxp3, ctla4, runx3, and cd25 were observed at both concentrations (except for ctla4 at 4%) at two
days post exposure (Figure 4B). Similarly, significant decreases in foxp3, ctla4, and cd25 mRNA were
observed in Tregs from 4% TDI-exposed mice at seven days post 4% TDI exposure (Figure 4C), further
indicating that these genes may be influenced by miR-210 (Figure 1A). Treg-specific expression of
runx3 was assayed in dLN Tregs during TDI sensitization. In contrast to the mRNA levels, increases in
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Figure 4. Mature miRNA and Runx3 expression increases in Tregs during TDI sensitization. RT-PCR
analysis of miR-210 (A) and Treg-related gene expression in the dLN Treg subset at two (B) and seven
days (C) post TDI exposure. Tregs were isolated as CD4+CD25+ cells and cellular purity was assessed
via flow cytometric staining for CD3+CD4+Foxp3+ events (2 days: % Tregs of all CD4+ events, mean,
n = 4–5 per group: Acetone: 83.8% ± 1.6%, 0.5% TDI: 67.1% ± 4.2%, and 4% TDI: 72.3% ± 1.9%; 7 days:
% Tregs of all CD4+ events: Acetone: 91%, 0.5% TDI: 88.4%, and 4% TDI: 86.7%). Flow cytometric
analysis of dLN Runx3+ Treg frequency (D) and number (E) following TDI sensitization. Bars represent
mean relative fold change (±SE) of 4–5 mice per group. Significance is indicated by * p ≤ 0.05 for (A–C)
and p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****) for 4% TDI or p ≤ 0.05 (ˆ), p ≤ 0.01
(ˆˆ), p ≤ 0.001 (ˆˆˆ), and p ≤ 0.0001 (ˆˆˆˆ) for 0.5% TDI compared to vehicle control (D,E).
3.5. The Ex Vivo Suppressive Capability of Tregs Is Influenced by miR-210 Levels
In order to examine the suspected inhibitory role of miR-210 on Tregs during TDI sensitization,
the functional capabilities of Tregs were tested in an ex vivo suppression assay. miR-210 mimic was
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transfected in selected wells utilizing a lipid-based transfection strategy and intracellular miR-210
mimic uptake was confirmed in these wells at the time of cellular harvest (Figure 5A). Interestingly,
following addition of the miR-210 mimic, miRNA-210 levels were almost 10-fold higher in wells
containing acetone Tregs compared to those with TDI Tregs (Figure 5A). No differences were noted
between miR-210 levels among the acetone and TDI groups treated with LO (Figure 5A). Significant
baseline Treg suppressive ability was observed in wells with Lipofectamine only and acetone-derived
Tregs as well as 4% TDI-derived Tregs (data not shown). This was not altered significantly upon the
addition of miR-210 mimic with the exception of the 1:1 ratio in wells with 4% TDI-derived Tregs
(data not shown). As previously evidenced [21], TDI-derived Tregs exhibited greater suppressive
capability than acetone-derived Tregs in mimic-treated wells for the 1:1, 2:1, 4:1, and 8:1 ratios
(Figure 5B). This increased function was observed in the presence of lower miR-210 levels suggesting
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Figure 5. Increased Treg suppression is associated with decreased miR-210 levels. A CFSE-based Treg
suppression assay was performed with Tregs from mice treated with acetone or TDI (seven days post
exposure) and the addition of iR-210 mimic. RT-PCR analysis of intracellular miR-210 expression
for acetone r TDI treated mice following addition f miR-210 mi ic or Lipof ctamine only (LO)
control (A). Statistical significance is represented by horizontal lines comparing indicated groups and
asterisks (compared to LO control) (p < 0.05). Functional capacity of Tregs based on percent dividing
CFSE+ naive conventional T cells (Tcon) at indicated ratios following addition of miR-210 mimic (B).
p values are represented by * (p < 0.05; comparison of each treatment group to 1:0 ratio from the same
chemical treatment group) or horizontal bars (comparison of identical ratios between different mimic
treatment groups). Bars represent mean relative fold change (± SE) of three replicates per group.
3.6. Further Investigation of miR-31 and -155 Suggest Additional Regulation of the TDI Sensitization
Response, Potentially Impacting miR-210 and Tregs
Evaluation of additional miRNAs was performed in an attempt to identify other potential factors
that might influence miR-210 and Treg function. miR-31 and -155 were selected since they have
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been identified to significantly increase in dLN expression earlier in TDI sensitization compared to
miRNA-210 (Figure 6A,B). Ex vivo target analysis was performed utilizing additional miRNA mimics
including miR-31 and -155 in order to further pursue the potential regulation of the Treg subset by
these miRNAs in addition to miR-210. Significantly increased intracellular levels of miR-31 (Figure 6C)
and miR-155 (Figure 6D) were confirmed 72 h following transfection and stimulation. Although
not statistically significant, apparent decreases in foxp3 expression were observed following miR-31
(Figure 6E) and miR-155 (Figure 6F) mimic transfection. No changes in expression were observed for




















(A) and  ‐155  (B)  levels were quantified via RT‐PCR at various  time points post TDI sensitization. 
Statistical significance is represented by ^ (0.5% TDI) and * (4% TDI) compared to vehicle control (p < 
















































































































































































































Figure 6. In vivo dLN miR-31 and -155 levels increase during TDI sensitization. Whole dLN miR-31 (A)
and -155 (B) levels were quantified via RT-PCR at various time points post TDI sensitization. Statistical
significance is represented by ˆ (0.5% TDI) and * (4% TDI) compared to vehicle control (p < 0.05).
Intracellular miR-31 (C), -155 (D) was quantified via RT-PCR in ex vivo stimulated samples (with
miR-31 or -155 mimic addition, respectively) after 72 h. (D–F) foxp3 expression was investigated in
cultures following miR-31 (D) and -155 (E) mimic treatment. Statistical significance is represented by
* when compared to lipofectamine only (LO) control (p < 0.05). (n = 3–5/group).
Treg-specific expression of miR-31 and miR-155 were also analyzed, revealing increased miR-31
levels two and seven days post 0.5% TDI exposure (Figure 7A,B) and increased miR-155 levels seven
days post 4% TDI exposure (Figure 7D). Since miR-31 was identified to increase in expression earlier
than miR-210 in the dLN and Tregs, miR-210 expression was evaluated in dLN cells treated with miR-31
and -155 mimics. However, no changes in expression were observed. Similarly, expression of miR-31
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and -155 was analyzed in cells treated with miR-210 mimic but no significant changes in expression
were observed (data not shown).
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Figure 7. Mature miR-31 and -155 expression increases in Tregs during TDI sensitization. RT-PCR
analysis of miR-31 (A,B) and -155 (C,D) expression in the dLN Treg subset at two and seven days
post TDI exposure. Tre s were isolated as CD4+CD25+ cells and cellular purity was assessed via flow
cytometric staining for CD3+CD4+Foxp3+ events (2 days: % Tregs of all CD4+ event , mean, n = 4–5 per
group: Aceton : 83.8% ± 1.6 , . I: 67.1% ± .2%, and 4 TDI: 72.3% ± 1.9%; 7 days: % Tregs of
all CD4+ events, Acetone: 91%, 0.5% TDI: 88.4%, and 4% TDI: 86.7%). Bars represent mean relative fold
change (± SE) of 4–5 mice per group. Statistical significance is represented by * (p < 0.05).
4. Discussion
The occupational use of sensitizing chemicals such as TDI remains a significant public health
concern. There are no validated hazard identification strategies for respiratory sensitizers like TDI
and the complete immunologic mechanisms of sensitization have not been elucidated for these agents,
hindering development of appropriate preventative assays. This justifies research pertaining to the
identification of novel cellular subsets and epigenetic regulatory mechanisms such as miRNAs that may
be involved in the respiratory chemical sensitization process. Following the identification of several
upregulated dLN miRNAs during TDI sensitization, these molecules were investigated, specifically in
relation to Treg development and functionality. To our knowledge, this is the first work that functionally
investigates miRNAs in a model of TDI-induced chemical sensitization.
miRNAs are powerful regulatory molecules which have been implicated in a number of
immunologic states and conditions, including allergic disease [24–26]. Specifically, miR-155 has
demonstrated a critical role in the development of antibody responses and germinal center function [27],
miR-326 has been shown to regulate Th17 differentiation, exhibiting critical involvement in multiple
sclerosis pathogenesis [28], and in vivo miR-126 inhibition reduces a house dust mite-induced
asthmatic phenotype, demonstrating the importance of this miRNA in the regulation of Th2 responses
and allergic asthma [24]. Vennegaard et al. described upregulation of several miRNAs, including
Genes 2017, 8, 9 12 of 16
miR-21, in skin biopsies from patients with allergic responses to diphenylcyclopropenone and in
a murine model of dinitrofluorobenzene (DNFB) allergic contact dermatitis [17]. Additionally, previous
work from our groups identified upregulation of several miRNAs, including miR-31, -155, and -210,
in a murine model of epicutaneous TDI sensitization [1]. These ubiquitous signaling molecules are
well-established mediators of many of signaling pathways in a number of cell types; however, their
role in chemical sensitization is not well understood. For the work described in this manuscript,
miR-210 was selected for additional investigation since it has been predicted and demonstrated to
target Treg-related genes. In addition, its role in chemical sensitization and Treg regulation has not yet
been described.
The expression of miR-210 was quantified in a variety of tissues and cellular subsets in a murine
model of TDI sensitization. Consistent with previous findings [1], increased expression of miR-210
in the dLN was also demonstrated in the present study during TDI sensitization (Figure 1A).
In addition, increased expression of miR-210 was also identified in Tregs during TDI sensitization
(Figure 4A). Since miRNA can be transported to cells via mechanisms such as exosomal transport,
experiments to determine if cells are actively producing miR-210 following TDI exposure were
conducted. The expression of pri-miRNA indicates gene level expression, presumably within the cell
type tested. Pri-miR-210 was detected in the dLN and CD4+ subsets four days post TDI exposure
(Figure 1B), indicating that miR-210 is being expressed in this tissue by CD4+ T cells. Interestingly,
although they were detectable, pri-miR-210 levels significantly decreased in CD4+ T cells four days
post 4% TDI exposure compared to equivalent cells in acetone-exposed mice, potentially indicating that
the majority of mature miR-210 in the dLN is being produced by another cell type, is being transported
from another tissue, or is being transcriptionally downregulated at this point, the peak of mature
miR-210 levels in the dLN. While pri-miR-210 levels in Tregs were not investigated in the current study,
previous studies have demonstrated miR-210 expression following the polarization of naïve T cells
into Tregs [29].
Since Tregs have been implicated as regulators of TDI sensitization [21] and miR-210 expression
has been shown to increase in Tregs following TDI sensitization (Figure 4A), an ex vivo target analysis
system was designed in order to directly examine the effects of miR-210 on Treg-related genes. Selected
genes identified as target of miR-210 included foxp3, the master transcription factor of the Treg subset;
and runx3, a transcription factor that signals upstream of foxp3 by binding to this gene’s promoter [30].
Additionally, cd25 and ctla4 were investigated as important Treg-related genes as they are involved
in IL-2 signaling and proliferation along with direct suppressive functions, respectively. This setup
revealed a potential role for miR-210 in the downregulation of Treg-associated genes (foxp3 and cd25;
Figure 2B) following the addition of miR-210 mimic. In addition foxp3 and runx3 dLN expression
decreased in the dLN at various time points following TDI exposure (Figure 3A,B) which is consistent
with our previously reported findings [21]. The earlier decrease in runx3 expression observed at four
days post 4% TDI exposure may be reflective of the upstream signaling activity of this transcription
factor in relation to foxp3 (Figure 3B). While the findings for the ex vivo assay did not reach statistical
significance, further support for Treg-associated genes as miRNA targets was provided by in vivo
data. Interestingly, whole dLN expression of ctla4 and cd25 increased at one, two and four days
post 4% TDI exposure (Figure 3C,D) which is likely a reflection of the activation of both Tregs and
conventional T cells as elevated protein expression of these molecules is observed in Tregs at these
time points [21] and would likely be increased in conventional T cells involved in TDI sensitization
as well. In Tregs, decreases in foxp3, cd25 and ctla4 were observed at two and seven days with runx3
only being decreased at the earlier time point post TDI exposure (Figure 4B). These early changes in
Treg factors provide further support that additional factors might be involved in Treg regulation since
peak increases in miR-210 occur later than two days; accordingly, miR-31 was shown be increased at
this time point. In contrast to the transcript, the expression kinetics of Runx3 increased following TDI
exposure (Figure 4D). This expression pattern was similar to other Treg proteins such as CD25 and
Foxp3 (which are represented by the general Treg population) and Treg-specific CTLA4 expression,
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which have previously been investigated during TDI sensitization [21]. The kinetics of Tregs bearing
these molecules tended to peak at four days post TDI exposure with a relative decrease in both cellular
frequency and number at seven days post TDI exposure [21]. In relation to miR-210 expression kinetics,
this data may suggest that miR-210 has a regulatory role on the Treg subset, as its expression wanes in
concert with the general Treg population as well as CTLA4+ and Runx3+ Tregs. Additionally, miR-210
is a putative runx3 target, suggesting a potential direct effect on this gene [1]. Collectively, this data is
suggestive of Treg regulation with visible effects on the expression of proteins beginning at Day 7 post
TDI exposure. miR-210 expression remains elevated in the dLN throughout nine days post 0.5% and
4% TDI exposure (Figure 1A) and in Tregs at seven days post 0.5% and 4% TDI exposure (Figure 4A).
Due to the potential link between miR-210 and Treg-related gene expression, the functional
capabilities of Tregs (acetone and TDI-derived) were examined in the presence and absence of miR-210
mimic. Interestingly, it appeared that miR-210 levels were lower in wells containing Tregs from
TDI-treated mice and miR-210 mimic compared to wells with acetone-derived Tregs and miR-210
mimic (Figure 5A). The increased suppressive capability of TDI Tregs with miR-210 mimic (Figure 5B)
may be a reflection of reduced miR-210 levels, as we hypothesize that miR-210 is inhibiting Treg
differentiation and/or function. This finding suggested that other regulatory factors including other
miRNAs might be involved in the regulation of Treg function. Complex interactions and interplay
have often been reported for other miRNAs [31], therefore this concept was evaluated in the current
study. Typically, direct miRNA–miRNA interactions are mediated by reverse complementary binding,
resulting in the formation of duplexes [31]. Additionally, indirect miRNA–miRNA interaction may
occur via target gene interaction; e.g., if a miRNA targets a gene that induces a different miRNA,
this miRNA is being regulated by its own species.
miRNA-31 and-155 were further investigated for the potential to regulate the expression of
miR-210 as they were identified to increase at early time points in TDI sensitization in the dLN
(Figure 6A (miR-31) and B (miR-155)) and Tregs (Figure 7A (miR-31)). Similarly to miR-210, miR-31 and
-155 were shown to potentially downregulate foxp3 expression in this assay (Figure 6E,F). Although
limitations in the assay sensitivities did not reflect significant changes, this may be reflective of
a direct effect on foxp3 or an indirect effect on this gene via other signaling pathways such as miR-210.
These alterations are in accordance with recent findings pertaining to miRNA–mRNA interactions.
miR-31 may indirectly target foxp3, leading to suppressed iTreg development [19], accounting for
the potential decreases in this gene evidenced following miR-31 mimic transfection. In addition,
miR-31 increases earlier when more persistent decreases in foxp3 were observed. Additionally, miR-155
expression appears to be controlled by foxp3 in Tregs via binding to the intron within the DNA sequence
encoding Bic, the precursor transcript of miR-155; accordingly, Treg miR-155 levels have been shown to
be highly responsive to foxp3 levels [32]. This regulation may be interrupted by abnormally high levels
of miR-155 in the mimic transfection system, resulting in decreased foxp3 expression in these conditions
via signaling feedback. This data suggests that miR-31 and -155 may be influencing the expression of
miR-210 and/or Tregs, possibly acting as early signaling mediators in the TDI sensitization response.
The lack of significance associated with the ex vivo experiments conducted in this work could
be a reflection of experimental variability associated with similar assays and temporal discrepancies
associated with signaling events. The ex vivo system displays several limitations, explaining the
utilization of the in vivo TDI sensitization model in the target investigation as well. The Treg-related
gene alterations that were observed as a consequence of miRNA mimic transfections in this system
may indicate direct and/or indirect targeting by the miRNA. We propose that for the majority
of miRNA–mRNA interactions investigated in our model, regulation is indirect, as few, if any,
putative binding sites were identified for many of the potential targets and the corresponding miRNA.
For example, miR-210 is predicted to target the 3′ UTR of runx3 [1] and although we did not observe
significant alterations in runx3 expression following miR-210 mimic transfection in our ex vivo system,
the in vivo expression kinetics of runx3 suggest potential regulation. The ubiquitous nature of miRNAs
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and their involvement in various signaling processes accounts for their functional significance but can
also cloud investigations into their mechanistic functions.
It is important to note that the increases in miRNA expression were not dependent on the irritant
response, as dLN miR-210 levels significantly increased (Figure 4A) following the non-irritating [21]
0.5% TDI exposure. As 4% TDI exposure causes significant dermal irritation [21], ear miR-210
expression was analyzed at both non-irritant (0.5%) and irritant (1%, 2%, and 4%) TDI concentrations,
revealing significant increases in dLN at both non-irritant and irritant doses (Figure 1A). In addition,
other miRNAs including miR-22, -31, and -301a were also shown to increase significantly in expression
regardless of the irritant status of the TDI dose (data not shown). This data prompts insight into
the concept of the “two-signal” sensitization hypothesis which states that antigen delivery alone is
insufficient for effective immunological priming but rather a second, innate signal is necessary to ensure
the development of sensitization [33,34]. As noted in previous studies, the irritant response appears
to be a prerequisite for strong sensitization responses in the case of dermal TDI sensitization [21].
Regardless, the expression of multiple miRNAs in the dLN appears to be due to the sensitization
response alone and not significantly influenced by the irritant component of this response, which may
be revealing as to their supposed functional roles in the sensitization response and may suggest
potential utility as biomarkers of sensitization.
These studies reveal a potential role for miR-210 in a murine model of dermal TDI sensitization
(Figure 8). Additionally, miR-31 and miR-155 were investigated for their regulatory potential in this
response. The investigation of novel mediators of chemical-induced allergic disease is important
for the overall understanding of the mechanisms involved in these responses. Therefore, this data
may result in enhanced understanding of the mechanisms involved in chemical sensitization and
could potentially aid in the development of hazard identification strategies for respiratory chemical
sensitizers. In conclusion, we have demonstrated that miR-210 may negatively influence the
differentiation and/or function of Tregs via direct targeting of runx3 and/or indirect actions on other
Treg-related genes. These findings suggest that these miRNAs may work in concert to affect the
differentiation and function of Tregs as well as the expression and function of miR-210.Genes 2017, 8, 9  15 of 17 
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Figure 8. Proposed model of select d miRN ion on the regulatory T cell pathway. Integral
components of the Treg activation pathway are highlighted alongside putative direct targets or key
players indirectly impacted by miRNA-210 (indicated by *), -31 (indicated by +), and -155 (indicated by
$). Legend: CD28, Cluster of differentiation 28; CD25, IL-2 receptor alpha (in complex with IL-2Rβ and
γc); CTLA4, Cytotoxic T-lymphocyte associated protein 4; Foxp3, Forkhead box P3; P, Phosphate group;
Runx3, Run related transcription factor 3; Smad5, Mothers against decapentaplegic homolog 5; Stat5,
Signal transducer and activator of transcription 5, TCR, T cell receptor; TDI-hp, Toluene diisocyanate
haptenated complex; TGF-β1, Transforming growth factor beta 1.
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